A study showed that naltrexone and bupropion treatment was associated with a total body weight loss (TBWL) of 5.2%
This is an exciting development, which follows the discovery from CV outcomes trials (CVOTs) that some antidiabetic agents have a cardioprotective effect in at-risk patients [7,8,9,10]
Does the post argue medication replaces behavior change
Reduces energy intake, likely mechanisms for semaglutide-induced weight loss include less appetite and food cravings, better control of eating and lower relative preference for fatty, energy-dense foods
3,5 A small number of people may notice low mood, flatness, or loss of interest on a GLP-1
We have individuals as young as 12 that can be on these therapies, and I have patients in their 90s on these therapies